Bivalirudin for patients with acute coronary syndromes.

By G. Stone, B. McLaurin, David A. Cox, M. Bertrand, A. Lincoff, Jeffrey W. Moses, Harvey D. White, S. Pocock, James H. Ware, F. Feit and 42 more. New England Journal of Medicine, 2006

1,349 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Hematology, Surgery

View Paper: https://www.semanticscholar.org/paper/7b6acb90d8d59f91c6db4aa22c48b17c6f34ceba

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Harvey D. White
2. Rick A. Nishimura
3. J. Halperin
4. Hani Jneid
5. Allan S. Jaffe
6. M. Creager
7. C. Yancy

In Surgery

1. Harvey D. White
2. M. Creager

Citations in the corpus

• 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. (2008, methodology): “The recommendations in the ACC/AHA 2007 UA/ STEMI Guidelines (14) recognize recent data from the CUITY (Acute Catheterization and Urgent Intervention riage strategY) trial, which showed that in patients with CS who were undergoing invasive treatment, bivalirudin lone was associated with rates of isc”
• 2018 ESC/EACTS Guidelines on myocardial revascularization. (2019, neutral): “However, the reduction of bleeding risk was linked to unbalanced use of GP IIb/IIa inhibitors predominantly with UFH.”
• 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, methodology): “An early invasive strategy (diagnostic angiography with intent to perform revascularization if appropriate based on coronary anatomy) is indicated in initially stabilized patients with NSTEACS (without serious comorbidities or contraindications to such procedures) who have an elevated risk for clini”
• Acute Myocardial Infarction in Women: A Scientific Statement From the American Heart Association (2016, methodology): “In those patients, it is reasonable to use bivalirudin monotherapy in preference to these agents.(216,217,271,272) Patients treated with fondaparinux, a selective factor Xa inhibitor, had ischemic outcomes similar to those treated with enoxaparin or unfractionated heparin.”
• 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, methodology): “TABLE 7 Summary of Recommendations for Initial Antiplatelet/Anticoagulant Therapy in Patients With Definite or Likely NSTE-ACS and PCI Recommendations Dosing and Special Considerations COR LOE References Aspirin Non–enteric-coated aspirin to all patients promptly after presentation 162 mg–325 mg I A”